Lawsuits allege that popular antipsychotic medications Risperdal (risperidone), Invega (paliperidone), and Zyprexa (olanzapine) significantly increase breast cancer risk in both women and men. Multiple large-scale studies show these drugs can raise prolactin hormone levels, which can trigger cancer development.
These antipsychotic medications work by blocking dopamine receptors in the brain, which removes the body's natural control over prolactin hormone production. When prolactin levels are elevated, multiple studies have shown this can activate biological pathways that promote breast cancer cell growth.
Wisner Baum was the first law firm to file a breast cancer lawsuit specifically targeting antipsychotic manufacturers, including Johnson & Johnson, Janssen Pharmaceuticals, and Eli Lilly. Our lawsuit alleges the drug makers have known about the breast cancer risk for decades, yet failed to adequately warn patients and doctors.
See if you qualify for an antipsychotics lawsuit by filling out our free case evaluation form. To schedule a consultation, call our legal team at (310) 207-3233.
You may qualify for a legal claim if:
The fastest way to find out whether you qualify for a case is to complete our contact form or give us a call at (310) 207-3233.
A statute of limitations is a legal deadline for filing a lawsuit. If you miss this deadline, you may lose the right to seek compensation, no matter how strong your case may be. It is in your best interest to consult with a lawyer as soon as possible.
The following damages may be available by pursuing a lawsuit:
These cover provable financial losses caused by your diagnosis:
Compensation for intangible harms, including:
Lawsuits may also result in punitive damages, which are monetary penalties awarded to the plaintiffs in addition to compensatory damages. Punitive damages are designed to punish defendants who recklessly disregard human safety and deter similar harmful conduct from happening again.
A breast cancer diagnosis creates profound physical, emotional, and financial consequences. Patients who took an antipsychotic and later developed breast cancer should not face these burdens alone—especially when pharmaceutical companies allegedly failed to warn about known cancer risks.
Our lawsuits allege the drug maker defendants in this litigation knew about breast cancer risks as early as the 1990s but failed to warn patients and doctors. According to legal filings, clinical trials conducted as part of the approval process showed antipsychotics can substantially contribute to breast cancer development, yet manufacturers concealed this evidence while aggressively marketing these drugs to vulnerable populations
You need a law firm with a proven track record of success in similar cases on your side. At Wisner Baum, our attorneys have won some of the most highly publicized prescription drug cases. Our settlements in litigation against Big Pharma include:
Put our experience and resources to work for you. Let us fight for full and fair compensation so you can focus on what matters most: your health and well-being.
To learn more about your legal rights, fill out our contact form or call our legal team anytime at (310) 207-3233.
How long do I have to file an antipsychotic lawsuit?
The deadline to file your case is dictated by the specific statute of limitations. Because these deadlines can permanently bar your claim, contact an antipsychotics attorney immediately to determine your specific deadline.
How much does it cost to hire a lawyer for an antipsychotic lawsuit?
Nothing out of pocket. Our attorneys work on a contingency fee basis, meaning you pay no upfront costs or attorney fees unless we win your case. We offer free consultations to evaluate your potential claim.
"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case.
The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
$289.2 million jury verdict in Monsanto Roundup trial
Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma.
Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million.
Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.